Trial Profile

A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tisagenlecleucel (Primary) ; Cyclophosphamide; Cytarabine; Etoposide; Fludarabine; Tocilizumab
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use
Acronyms CASSIOPEIA
Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

26 Jul 2024 Status changed from recruiting to active, no longer recruiting.
10 Jun 2024 Planned number of patients changed from 120 to 121.
12 Apr 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com